Zacks: Analysts Anticipate Blueprint Medicines Co. (NASDAQ:BPMC) Will Announce Earnings of -$1.80 Per Share

Wall Street analysts expect Blueprint Medicines Co. (NASDAQ:BPMC – Get Rating) to report earnings of ($1.80) per share for the current fiscal quarter, according to Zacks Investment Research. Eight analysts have issued estimates for Blueprint Medicines’ earnings, with the lowest EPS estimate coming in at ($2.22) and the highest estimate coming in at ($1.48). Blueprint Medicines reported earnings of ($1.72) per share in the same quarter last year, which would indicate a negative year-over-year growth rate of 4.7%. The firm is expected to issue its next quarterly earnings report on Monday, January 1st.

According to Zacks, analysts expect that Blueprint Medicines will report full-year earnings of ($7.46) per share for the current year, with EPS estimates ranging from ($9.02) to ($6.19). For the next fiscal year, analysts expect that the firm will report earnings of ($5.88) per share, with EPS estimates ranging from ($7.81) to ($3.82). Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side research analysts that follow Blueprint Medicines.

Blueprint Medicines (NASDAQ:BPMC – Get Rating) last issued its earnings results on Wednesday, February 16th. The biotechnology company reported ($0.99) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.71) by ($0.28). Blueprint Medicines had a negative net margin of 357.66% and a negative return on equity of 31.04%. The firm had revenue of $107.00 million during the quarter, compared to analyst estimates of $104.14 million. During the same quarter in the prior year, the firm posted ($1.53) EPS. The firm’s revenue for the quarter was up 213.8% on a year-over-year basis.

BPMC has been the topic of several recent analyst reports. Morgan Stanley reduced their target price on shares of Blueprint Medicines from $111.00 to $92.00 and set an “equal weight” rating on the stock in a research note on Tuesday, February 1st. Wedbush restated an “outperform” rating and issued a $126.00 target price on shares of Blueprint Medicines in a research note on Monday, February 28th. JMP Securities reiterated a “buy” rating and set a $152.00 price target on shares of Blueprint Medicines in a research report on Monday, April 11th. Stifel Nicolaus upped their price target on shares of Blueprint Medicines from $100.00 to $105.00 and gave the stock a “buy” rating in a research report on Friday, March 4th. Finally, StockNews.com initiated coverage on shares of Blueprint Medicines in a research report on Thursday, March 31st. They set a “sell” rating on the stock. One equities research analyst has rated the stock with a sell rating, four have given a hold rating, five have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $106.45.

In other news, CEO Jeffrey W. Albers sold 5,000 shares of the company’s stock in a transaction dated Wednesday, April 6th. The stock was sold at an average price of $70.11, for a total value of $350,550.00. Following the completion of the sale, the chief executive officer now directly owns 183,243 shares of the company’s stock, valued at approximately $12,847,166.73. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Ariel Hurley sold 761 shares of the company’s stock in a transaction dated Thursday, March 3rd. The shares were sold at an average price of $60.27, for a total value of $45,865.47. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 10,575 shares of company stock valued at $677,614. 3.34% of the stock is currently owned by company insiders.

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. BlackRock Inc. increased its stake in Blueprint Medicines by 2.7% during the 4th quarter. BlackRock Inc. now owns 5,336,874 shares of the biotechnology company’s stock worth $571,632,000 after purchasing an additional 138,860 shares in the last quarter. Wellington Management Group LLP increased its stake in Blueprint Medicines by 58.7% during the 3rd quarter. Wellington Management Group LLP now owns 3,199,041 shares of the biotechnology company’s stock worth $328,893,000 after purchasing an additional 1,182,979 shares in the last quarter. William Blair Investment Management LLC increased its stake in Blueprint Medicines by 1.8% during the 4th quarter. William Blair Investment Management LLC now owns 1,747,721 shares of the biotechnology company’s stock worth $187,198,000 after purchasing an additional 30,557 shares in the last quarter. State Street Corp increased its stake in Blueprint Medicines by 2.6% during the 4th quarter. State Street Corp now owns 1,731,470 shares of the biotechnology company’s stock worth $185,458,000 after purchasing an additional 43,086 shares in the last quarter. Finally, JPMorgan Chase & Co. increased its stake in Blueprint Medicines by 8.3% during the 4th quarter. JPMorgan Chase & Co. now owns 1,644,161 shares of the biotechnology company’s stock worth $176,106,000 after purchasing an additional 126,350 shares in the last quarter.

Shares of NASDAQ:BPMC opened at $63.52 on Friday. Blueprint Medicines has a 52 week low of $53.26 and a 52 week high of $117.86. The company’s fifty day moving average is $64.50 and its 200-day moving average is $85.37. The company has a market capitalization of $3.76 billion, a PE ratio of -5.79 and a beta of 0.95.

Blueprint Medicines Company Profile (Get Rating)

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of non-advanced SM and other mast cell disorders; and Fisogatinib, an orally available and potent inhibitor for the treatment of hepatocellular carcinoma.

Read More